InvestorsHub Logo
Post# of 251306
Next 10
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

Re: iandy post# 138161

Friday, 03/02/2012 12:21:50 PM

Friday, March 02, 2012 12:21:50 PM

Post# of 251306
Apropos of ponatinib being a potent RET inhibitor, it's very recently been discovered that a RET fusion occurs in about 2% of NSCLC:

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

Doron Lipson, Marzia Capelletti, Roman Yelensky, Geoff Otto, Alex Parker, Mirna Jarosz, John A Curran, Sohail Balasubramanian, Troy Bloom, Kristina W Brennan, Amy Donahue, Sean R Downing, Garrett M Frampton, Lazaro Garcia, Frank Juhn, Kathy C Mitchell, Emily White, Jared White, Zac Zwirko, Tamar Peretz, Hovav Nechushtan, Lior Soussan-Gutman, Jhingook Kim, Hidefumi Sasaki, Hyeong Ryul Kim et al.
AffiliationsContributionsCorresponding authors
Nature Medicine (2012) doi:10.1038/nm.2673
Received 07 October 2011 Accepted 13 January 2012 Published online 12 February 2012

Applying a next-generation sequencing assay targeting 145 cancer-relevant genes in 40 colorectal cancer and 24 non–small cell lung cancer formalin-fixed paraffin-embedded tissue specimens identified at least one clinically relevant genomic alteration in 59% of the samples and revealed two gene fusions, C2orf44-ALK in a colorectal cancer sample and KIF5B-RET in a lung adenocarcinoma. Further screening of 561 lung adenocarcinomas identified 11 additional tumors with KIF5B-RET gene fusions (2.0%; 95% CI 0.8–3.1%). Cells expressing oncogenic KIF5B-RET are sensitive to multi-kinase inhibitors that inhibit RET.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.